How decentralisation can fill the gaps in Alzheimer’s research
In a new era of Alzheimer’s disease research, the emergence of blockbuster therapies like Eli Lilly’s Kisunla (donanemab) and Eisai…
In a new era of Alzheimer’s disease research, the emergence of blockbuster therapies like Eli Lilly’s Kisunla (donanemab) and Eisai…
GE HealthCare has announced the Food and Drug Administration (FDA) 510(k) clearance for its SIGNA MAGNUS magnetic resonance imaging (MRI)…
Veravas and Phanes Biotech have announced a partnership for the joint development of a blood-based tau pathology test for detecting…
Eli Lilly Saudi Arabia and King Faisal Specialist Hospital & Research Centre (KFSHRC) have teamed up to make KFSHRC’s Neuroscience…
Researchers at University College London (UCL) and University College London Hospitals (UCLH) in the UK have developed an AI-based tool…
ONWARD Medical has acquired an exclusive licence from CEA for the development and commercialisation of the WIMAGINE Brain-Computer Interface (BCI)…
PhotoPharmics has announced a pivotal development in its FDA "Light for PD" clinical trial of the Celeste therapeutic device, with…
A device currently in clinical trials for hydrocephalus could be used to deliver gene therapies to the central nervous system…
C2N Diagnostics has received an investment of up to $7.025m from the Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator for its…
The US Food and Drug Administration (FDA) has approved Neuros Medical’s electrical nerve stimulation system for the treatment of pain…